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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.004Substance abuse is a major barrier in eradication of the HIV epidemic because it serves as a powerful
cofactor for viral transmission, disease progression, and AIDS-related mortality. Cocaine, one of the
commonly abused drugs among HIV-1 patients, has been suggested to accelerate HIV disease pro-
gression. However, the underlying mechanism remains largely unknown. Therefore, we tested whether
cocaine augments HIV-1eassociated CD4þ T-cell decline, a predictor of HIV disease progression. We
examined apoptosis of resting CD4þ T cells from HIV-1enegative and HIV-1epositive donors in our
study, because decline of uninfected cells plays a major role in HIV-1 disease progression. Treatment of
resting CD4þ T cells with cocaine (up to 100 mmol/L concentrations) did not induce apoptosis, but 200
to 1000 mmol/L cocaine induced apoptosis in a dose-dependent manner. Notably, treatment of CD4þ T
cells isolated from healthy donors with both HIV-1 virions and cocaine signiﬁcantly increased apoptosis
compared with the apoptosis induced by cocaine or virions alone. Most important, our biochemical data
suggest that cocaine induces CD4þ T-cell apoptosis by increasing intracellular reactive oxygen species
levels and inducing mitochondrial depolarization. Collectively, our results provide evidence of a synergy
between cocaine and HIV-1 on CD4þ T-cell apoptosis that may, in part, explain the accelerated disease
observed in HIV-1einfected drug abusers. (Am J Pathol 2014, 184: 927e936; http://dx.doi.org/
10.1016/j.ajpath.2013.12.004)This study was partly supported by National Institute on Drug Abuse/NIH
grants DA024558, DA30896, DA033892, and DIDARP R24DA021471
(C.D.), Research Center for Minority Institution grant G12MD007586,
Vanderbilt Clinical and Translational Science Award (CTSA) grant
UL1RR024975, and Meharry Translational Research Center CTSA grant
(National Center for Research Resources/NIH grant U54 RR026140, Na-
tional Institute on Minority Health and Health Disparities/NIH U54 grant
MD007593, and grant DA029506) that established the patient samples.
Disclosures: None declared.The HIV/AIDS pandemic has claimed the lives of an esti-
mated 35 million people (http://www.who.int/mediacentre/
factsheets/fs360/en/index.html, last updated October 2013).
Although anti-retroviral therapy (ART) has dramatically
reduced HIV/AIDS-related mortality,1 substance use is a
major barrier for combating theHIV/AIDS pandemic because
it is associated with transmission, delayed diagnosis, delayed
initiationof therapy, andpoor adherence to therapy.2Cocaine is
a commonly abused drug among HIV-1 patients,3e5 and
studies suggest that cocaine abuse may accelerate HIV-1 dis-
ease progression. For example, Vittinghoff et al6 documented
an increased risk ofHIV-1 disease progression among frequent
cocaine users. Arnsten et al7,8 have reported that active cocaine
use strongly predicts failure to viral suppression. Similarly,stigative Pathology.
.Webber et al9 suggested that use of cocaine, alongwith alcohol,
might accelerateHIV-1 disease progression. In addition, Lucas
and colleagues10e12 found that cocaine users have inferior
virological and immunological responses to ART. The effects
of cocaine on disease progression in these studies can be
Pandhare et alattributed, in part, to nonadherence to ART, because substance
use is often associatedwith reduced adherence and/or access to
ART.13 There are also reports that did not ﬁnd signiﬁcant as-
sociation between cocaine abuse and HIV-1 disease progres-
sion.14,15 However, Baum et al3 found that cocaine users have
higher viral load and were twice as likely to progress to AIDS
when controlled for ART use. Notably, Palepu et al16 reported
that HIV-1epositive drug users, while taking ART, were less
likely to suppress the viral load. Recently, Rasbach et al17 have
suggested that active cocaine use among HIV-1 patients is
associated with lack of virological suppression, independent
of ART adherence. Although in vitro studies suggest that
increased HIV-1 replication by cocaine18e21 may play a role,
the mechanism by which cocaine accelerates HIV-1 disease
progression remains unclear. Therefore, we evaluated whether
cocaine could potentiate HIV-1einduced CD4þ T-cell apo-
ptosis becauseCD4þT-cell decline is an important predictor of
HIV-1 disease progression. Our data suggest a synergy be-
tween cocaine and HIV-1 on CD4þ T-cell apoptosis and
highlight the molecular interplay between cocaine abuse and
HIV-1 disease progression.
Materials and Methods
Study Subjects
Blood fromHIV-negative individualswas purchased from the
New York Blood Center (New York City, NY), as per the
Meharry Medical College (Nashville, TN) Institutional Re-
view Board. HIV-infected individuals were recruited through
Institutional Review Boardeapproved protocols from Van-
derbilt University Medical Center (Nashville). Inclusion
criteria included documented HIV infection and>18 years of
age. Individuals taking ART were excluded from this study.
All individuals provided written informed consent.
Isolation and Treatment of CD4þ T Cells
Peripheral blood mononuclear cells (PBMCs) were isolated as
per our published method.18,22 Resting CD4þ T cells were iso-
lated from PBMCs by negative selection using a CD4þ T-cell
Isolation Kit II (Miltenyi Biotec, Auburn, CA) and cultured in
RPMI 1640 medium (Life Technologies, Carlsbad, CA) with
20%heat-inactivated fetal bovine serum,2mmol/LL-glutamine,
and antibiotics. The purity of the cells was analyzed by
ﬂuorescence-activated cell sorting (FACS), as per our published
methods.18 Cocaine hydrochloride was obtained from Sigma
(St.Louis,MO).A total of 2 106CD4þTcells/mLmediawere
seeded in culture dishes overnight at 37C and were exposed to
cocaine and/orHIV-1 virions for 24 hours. Cocaine (1mmol to 1
mmol) was used to cover a wide range of physiological con-
centrations reported among cocaine addicts.23e28 The superna-
tants of infected ACH-2 cells were used as the source of X4
tropic HIV-1 LAI virions.18 Infectivity, viral p24 ELISA, and
measurement of intracellular viral p24wereperformedasper our
published protocol.18 Apoptosis was measured by annexin V928(AV) and propidium iodide (PI) staining using ﬂow cytometry,
as per our published methods.18,22
Measurements of ROS and Mitochondrial Membrane
Potential
2,7-Dichlorohydroﬂuorescein diacetate (DCF; Sigma) was
used to measure intracellular reactive oxygen species (ROS).
After treatment, cellswere centrifuged,washedwith PBS, and
exposed to serum-free, phenol redefree medium containing
10 mmol/L DCF for 30 minutes in the dark. After two washes,
ﬂuorescence was measured by ﬂow cytometry. In parallel,
cells were solubilized with 0.5% SDS and 5mmol/L Tris HCl
(pH 7.5) and the ﬂuorescence intensity of the lysate was
determined by spectroﬂuorometer, with excitation and emis-
sion wavelengths of 485 and 520 nm, respectively. Mito-
chondrial membrane potential was analyzed by using the
ﬂuorescent dye, 5,50,6,60-tetraethylbenzimidazolcarbocya-
nine iodide (JC-1; Cayman Chemical). After treatment, cells
were stained with JC-1 dye for 30 minutes at 37C. After two
washes, the cells were resuspended in buffer and the ﬂuo-
rescence was measured, with excitation and emission wave-
lengths of 485/567 and 520/620 nm, respectively.
Measurement of Apoptosis of CD4þ T Cells from
HIV-Positive Individuals
We used cryopreserved PBMCs from 15 ART-naïve HIV-
1einfected patients. All laboratory procedures were per-
formed blinded to case-control status. These PBMCs were
thawed, washed, and cultured, with or without cocaine for 24
hours. These cells were then washed and stained with a panel
of antibody that includes staining with live/dead aqua stain,
CD4, HLA-DR (immune activation marker), and CD69 (early
immune activationmarker). ApoptosiswasmeasuredwithAV
and live/dead aqua.Datawere acquired byFACSandanalyzed
with FacsDIVA and/or Flowjo software version 7.6.5.
Statistical Analysis
All the experiments were repeated three times, with each
experiment containing triplicate samples. The signiﬁcance
of differences between control and treated samples was
determined by one-way analysis of variance. Comparisons
between two groups were conducted using a Student’s t-test.
Results were considered signiﬁcant when P < 0.05. Data are
presented as means  SD. Statistical analyses were per-
formed with Microsoft Excel 2007.
Results
Cocaine Enhances HIV-1eInduced Apoptosis of
Uninfected Resting CD4þ T Cells
HIV-1 infection causes decline of both infected and uninfected
CD4þ T cells. However, decline of uninfected cells plays a
critical role in HIV-1eassociated immunodeﬁciency.29e32ajp.amjpathol.org - The American Journal of Pathology
Cocaine Enhances CD4þ T-Cell ApoptosisTherefore, we examined the effects of cocaine onCD4þT-cell
apoptosis using uninfected resting CD4þ T cells from healthy
donors. These cells were treated with 1, 10, 100, 200, 500, and
1000 mmol/L cocaine, respectively, for 24 hours, and
apoptosis was measured by ﬂow cytometry using AV as the
early apoptosis marker and PI as the late apoptosis marker.
Data presented in Figure 1, A and B demonstrated that cells
treated with cocaine (up to 100 mmol/L) show a minimal in-
crease in AV staining compared with untreated cells. How-
ever, cocaine at concentrations of 200 to 1000mmol/L showed
a dose-dependent increase in the AV and total AV (AVþ and
AVþ/PIþ) staining (Figure 1B). This is consistent with cells
from six different donors that showed maximum increase
in AV and total AV staining with 1000 mmol/L cocaine
(Figure 1B). These results suggested that cocaine (up to
100 mmol/L) has a limited apoptotic effect on resting CD4þFigure 1 Effect of cocaine and HIV-1 virions on resting CD4þ T-cell apoptosis: R
and cells with>95%purity were used in the experiments. The resting CD4þ T cells we
byﬂow cytometry for AV and PI staining tomeasure early and late apoptosis, respecti
AVþ, PIþ, and AVþ PIþ cells (A). Data from cells isolated from six different donors s
AVþ PI) (B). Apoptosis of resting CD4þ T cells by HIV-1 virions. Cells were exposed to
for 24 hours, followed by ﬂow cytometry analyses for AV and PI staining (C and D). Re
PIþ, and AVþ PIþ cells (C). Data from cells isolated from six donors showing fold in
expressed as means  SD for three separate experiments conducted in triplicate. *
The American Journal of Pathology - ajp.amjpathol.orgT cells. However,>200 mmol/L cocaine induces CD4þ T-cell
apoptosis in a dose-dependent manner.
Then, we tested the cytotoxicity of HIV-1 virions toward
uninfected resting CD4þ T cells. We used the infectious X4
tropic HIV-1 LAI virions, because X4 virions are associated
with rapid CD4 T-cell loss and linked to HIV-1 disease
progression.33,34 The CD4þ T cells were exposed to
increasing amounts of virions (2, 5, 10, 20, 50, and 100
ng/mL of viral p24 protein equivalent) for 24 hours and
analyzed for the induction of apoptosis by AV and PI
staining (Figure 1, C and D). Treatment of cells with virions
(up to 50 ng/mL equivalent of p24) showed moderate-level
apoptosis, as illustrated by AVþ cells compared with un-
treated cells. However, cells treated with virions at 100
ng/mL of p24 showed an approximately ﬁvefold increase in
AV reactivity (Figure 1C). Predictably, lower amounts ofesting CD4þ T cells were isolated from the PBMCs of HIV-1enegative donors,
re treatedwith increasing concentrations of cocaine for 24 hours and analyzed
vely (A andB). Representative data fromone donor showing the percentage of
howing fold increase in AVþ cells, AVþ PIþ cells, and total AVþ cells (AV and
increasing amounts of HIV-1 virions (in terms of viral p24 protein equivalent)
presentative data using cells from one donor showing the percentage of AVþ,
crease in AVþ, AVþ PIþ, and total AVþ cells (AV and AVþ PI) (D). Results are
P < 0.05 for treated cells versus untreated control cells.
929
Pandhare et alvirions (1 to 10 ng/mL of p24) had no effect on AV staining
(data not shown). Consistent data were obtained with cells
from six different donors that demonstrated maximum
apoptosis with virions at 100 ng/mL of p24 (Figure 1D).
To study the effects of cocaine and HIV-1 together, we
used HIV-1 virions at 50 ng/mL of p24 and two concentra-
tions of cocaine (100 and 200 mmol/L). Virion-exposed cells
were treated with cocaine, and the total number of AVþ cells
was measured by FACS. Interestingly, in the presence of
virions, cocaine increased AV staining that is signiﬁcantly
higher compared with AV reactivity induced by cocaine or
virion alone (Figure 2, A and B). For example, 2.88% of cellsFigure 2 Synergy between cocaine and HIV-1 virions on resting CD4þ T-cell a
p24 equivalent) and/or cocaine (100 and 200 mmol/L, respectively), followed by ﬂo
cytometry data from one donor showing percentage of AVþ, AVþ PIþ, and PIþ c
increase in AVþ cells (B). CD4þ T cells were exposed to heat-inactivated HIV-1 vir
ﬂow cytometric analyses for AV and PI staining (C and D). Representative data fro
using cells from three different donors showing the percentage increase in AVþ cel
or 100 mmol/L cocaine, followed by ﬂow cytometric analyses for AV and PI staining
AVþ PIþ, and PIþ cells (E). Data using cells from three different donors showing th
for three separate experiments conducted in triplicate. *P < 0.05 for treated cel
930treated with 100 mmol/L cocaine were AVþ, whereas, in the
presence of virions, AV reactivity was increased to 11.5%
(Figure 2A). Furthermore, treatment with 200 mmol/L
cocaine increased the AVþ cells to approximately 23%,
suggesting that cocaine and HIV-1 likely have a synergistic
effect on resting CD4þ T-cell apoptosis. Notably, this syn-
ergy was abrogated with heat-inactivated virions, as depicted
by the comparable levels in AV staining between cells treated
with inactivated virions and cells treated with both cocaine
and inactivated virions (Figure 2, C and D). Similarly, use of
vesicular stomatitis virus G pseudotyped virions also lacked
the synergy between cocaine and HIV-1 virions (Figure 2, Epoptosis. Resting CD4þ T cells were exposed to HIV-1 virions (50 ng/mL of
w cytometric analyses for AV and PI staining (A and B). Representative ﬂow
ells (A). Data using cells from six different donors showing the percentage
ions (50 ng/mL of p24 equivalent) and/or 100 mmol/L cocaine, followed by
m one donor showing percentage of AVþ, AVþ PIþ, and PIþ cells (C). Data
ls (D). CD4þ T cells were exposed to VSV-Gepseudotyped HIV-1 virions and/
(E and F). Representative data from one donor showing percentage of AVþ,
e percentage increase in AVþ cells (F). Results are expressed as means  SD
ls versus untreated cells.
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Cocaine Enhances CD4þ T-Cell Apoptosisand F), highlighting the important role of HIV-1 envelope
protein in resting CD4þ T-cell apoptosis.
The Synergistic Effects of Cocaine and HIV-1 on CD4þ
T-Cell Apoptosis Are Not Due to Increased Infection or
Immune Activation
HIV-1 infection induces immune activation and CD4þ
T-cell apoptosis.35 Therefore, we tested whether the observed
apoptosis was due to infection. Our results showed that cells
exposed to virions (at 50 ng/mL of p24) exhibited no/negli-
gible infection (<2%), as measured by intracellular viral p24
protein by ﬂow cytometry (Supplemental Figure S1). This is
not surprising given that HIV-1 infects resting CD4þ T cells
at low levels, and detectable levels of p24 are not achieved
within 24 hours of infection.36 Notably, cocaine did not in-
crease infection (Supplemental Figure S1), indicating that
cocaine’s effect on HIV-associated CD4þ T-cell apoptosis is
not likely due to increased infection.
To test whether cocaine increased immune activation of
resting CD4þ T cells, we measured the expression of CD69
(early activation marker) and HLA-DR (late activation
marker). Our ﬂow analysis showed that cocaine treatment had
aminimal effect on the expression of eitherCD69 orHLA-DR
(Supplemental Figure S2A). Similar results were also ob-
tained when cells were stained for the IL-2 receptor, CD25
(Supplemental Figure S2B). HLA-DR expression in cells
treated with cocaine from six different donors also showed
minimal impact on immune activation (Supplemental
Figure S2C). These results suggested that the CD4þ T-cell
apoptosis by cocaine may not be due to increased infection or
immune activation.
Cocaine Accentuates HIV-1eInduced CD4þ T-Cell
Apoptosis by Increasing ROS and Mitochondrial
Membrane Depolarization
HIV-1einduced CD4þ T-cell apoptosis has been shown to
be mediated by mitochondrial oxidative stress, speciﬁcally
membrane depolarization and ROS.30,37e39 Therefore, we
tested whether cocaine enhances HIV-induced ROS gener-
ation in resting CD4þ T cells. To test this, virion-treated
CD4þ T cells were subjected to the peroxide-sensitive
ﬂuorescent probe, DCF, in the presence or absence of
cocaine. Our results demonstrated that individual virions (50
ng/mL of p24) or 200 mmol/L cocaine minimally increased
intracellular ROS (Figure 3, A and B). However, when
cocaine was added to cells treated with virions, there was a
signiﬁcant increase in ROS levels compared with cells
treated with virion or cocaine alone (Figure 3, A and B).
Furthermore, when cells were pretreated with N-acetyl
cysteine (NAC), a potent antioxidant before treatment, the
effects of cocaine on ROS generation in the HIV-1etreated
cells were diminished (Figure 3, A and B). Furthermore, AV
staining of NAC-treated cells showed that the antioxidant
also reduced the excessive apoptosis induced by cocaine andThe American Journal of Pathology - ajp.amjpathol.orgHIV-1 virions, as seen by the signiﬁcant decrease in total
number of AVþ cells (Figure 3C). Notably, the DCF ﬂuo-
rescence was unchanged when cells were treated with heat-
inactivated virions in the presence or absence of cocaine
(Figure 3, D and E). Collectively, these data illustrated that
increased ROS by cocaine and HIV-1 virions may play a
major role in CD4þ T-cell apoptosis.
Increased ROS is known to cause mitochondrial mem-
brane depolarization and induction of apoptosis.39e41
Therefore, we measured mitochondrial membrane potential
in resting CD4þ T cells treated with cocaine and/or virions
using the ratio of JC-1 green/red ﬂuorescence that has been
demonstrated to be a good indicator of mitochondrial depo-
larization.42 As shown in Figure 3F, the ratio of JC-1 red/
green ﬂuorescence was signiﬁcantly decreased (approxi-
mately 26%) when cells were treated with cocaine and vi-
rions compared with cells treated with virions (approximately
12%) or cocaine (approximately 9%) alone. Notably, cells
treated with NAC showed restoration of mitochondrial
membrane potential. These data strongly suggested that
cocaine accentuates HIV-1einduced mitochondrial depo-
larization in resting CD4þ T cells.
Cocaine Enhances Apoptosis of CD4þ T Cells Isolated
from HIV-1eInfected Subjects
Last, we evaluated whether cocaine can induce apoptosis of
resting CD4þ T cells of HIV-1einfected subjects that have
never received ART. First, we performed dose-response anal-
ysis using PBMCs from four HIV-1einfected individuals. The
PBMCswere treatedwith cocaine at concentrations of 1 to 1000
mmol/L for 24 hours, and apoptosis was measured by AV
staining. Similar to the data obtained with cells from HIV-
1enegative individuals, cocaine (up to concentrations of 100
mmol/L) had a minimal effect on CD4þ T-cell apoptosis.
However, a signiﬁcant increase in apoptosis was observed at
500 to 1000 mmol/L of cocaine, as illustrated by an increased
percentage of AVþ cells (Figure 4A). For example, approxi-
mately 20% of the cells treated with 1000 mmol/L cocaine
stained positive for AV (Figure 4A). We then evaluated 10
additional HIV-1epositive donors using 1000 mmol/L cocaine.
Cocaine treatment consistently enhanced AV staining, with an
increase in apoptosis from approximately 5% to 25% among
donors (Figure 4, B and C) and an average increase of
approximately 18.75% in AVþ staining (Figure 4D). This in-
crease is not due to immune activation because cocaine showed
a minimal effect on HLA-DR expression (Figure 4E). Collec-
tively, these data support our results from HIV-1enegative in-
dividuals for the effects of cocaine on CD4þ T-cell apoptosis.Discussion
Cocaine, a commonly used drug among HIV-1 patients,43
serves as a powerful cofactor for HIV-1 infection, disease
progression, and AIDS-related mortality.2e4,6,11,12,17,44e49931
Figure 3 Cocaine potentiates HIV-1einduced ROS generation and mitochondrial depolarization of resting CD4þ T cells. Primary uninfected resting CD4þ T
cells were treated with either 200 mmol/L cocaine and/or HIV-1 virions (50 ng/mL of p24 equivalent) for 24 hours and assayed for the production of ROS using
a DCF-based ﬂuorescence assay and a JC-1ebased mitochondrial depolarization assay, as described in Materials and Methods. Cells were treated with 100
mmol/L NAC, concurrent with cocaine and/or HIV-1 virions. Representative spectra of DCF ﬂuorescence in cells from one donor (A). Fold increase in ROS
generation, as measured by DCF ﬂuorescence using cells from three different donors (B). Apoptosis was measured as the percentage increase in AVþ cells by
ﬂow cytometry using cells from three different donors (C). ROS measurements by DCF ﬂuorescence using heat-inactivated HIV-1 virions in the presence or
absence of cocaine (D and E). Representative spectra of DCF ﬂuorescence in cells from one donor (D). Fold increase in ROS generation using cells from three
different donors (E). CD4þ T cells were treated with 200 mmol/L cocaine and/or HIV-1 (50 ng/mL of p24) for 24 hours, and mitochondrial membrane potential
was measured by staining with JC-1 dye (F). The membrane potential was quantiﬁed as a ratio of the aggregate (red ﬂuorescence) to monomer JC-1 (green
ﬂuorescence) in the cells from three different donors. Results are expressed as means  SD for three separate experiments conducted in triplicate. *P < 0.05
for treated cells versus untreated cells.
Pandhare et alStudies suggest that cocaine-abusing HIV patients have
lower CD4þ T-cell counts and accelerated decline in CD4þ
T-cell number.45e50 There is also evidence that HIV-1e
negative cocaine addicts have reduced levels of total CD4þ
T cells compared with nonusers.50 Animal studies also
demonstrated that cocaine decreases the number of circu-
lating lymphocytes.51,52 However, the underlying mecha-
nism for the effects of cocaine on human CD4þ T-cell decline
remains unclear. Therefore, we evaluated the effects of
cocaine on the apoptosis of resting CD4þ T cells, because
decline of uninfected resting CD4þ T cells is proposed to be
the major driver of T-cell depletion in AIDS patients.29e32,35
We treated cells from HIV-1enegative and HIV-1epositive
donors with cocaine and found that cocaine at concentrations
of 1 to 100 mmol/L had a minimal effect on CD4þ T-cell932apoptosis. However, cocaine >100 mmol/L induced
apoptosis in a dose-dependent manner, with maximum
apoptosis induced with 1000 mmol/L (Figures 1 and 4).
Notably, cells from HIV-1 patients treated with 1000 mmol/L
cocaine showed higher levels of apoptosis (Figure 4A)
compared with the cells from healthy donors (Figure 1A).
This increased susceptibility may be due to an altered im-
mune system in HIV-1einfected patients, use of frozen cells
compared with the fresh cells of healthy donors, or treatment
of mixed PBMC cultures in HIV-1einfected patients
compared with the pure cultures of CD4þ T cells for healthy
donors. In addition, cocaine and other drug use among the
donors used cannot be excluded.
We used 1 to 1000 mmol/L cocaine to cover the wide range
of plasma concentrations reported in cocaine abusers. Forajp.amjpathol.org - The American Journal of Pathology
Figure 4 Cocaine enhances apoptosis of resting CD4þ T cells of HIV-1einfected patients. PBMCs of ART-naïve HIV-1epositive donors were thawed,
washed, and cultured overnight. Then, these cells were treated with cocaine in a dose-dependent manner for 24 hours, followed by measurement of apoptosis
by ﬂow cytometry. Percentage of AVþ CD4þ T cells from four different donors (A). Effects of 1000 mmol/L cocaine on CD4þ T-cell apoptosis, as determined by
AVþ staining using PBMCs of 10 different ART-naïve HIV-1epositive donors (B). Results in A and B are expressed as means  SD for three separate ex-
periments conducted in triplicate. *P < 0.05 for treated cells versus untreated cells. Relative percentage change (C) and average increase in CD4þ T-cell
apoptosis (D) as a function of cocaine treatment using PBMCs of 10 different ART-naïve HIV-1epositive donors. Effects of cocaine on CD4þ T-cell immune
activation, as measured by HLA-DR expression using PBMCs of eight different ART-naïve HIV-1epositive donors (E).
Cocaine Enhances CD4þ T-Cell Apoptosisexample, Blaho et al25 reported that serum levels in patients
admitted to the emergency department averaged approxi-
mately 1.0 mmol/L. Mittleman and Wetli26 detected a mean
concentration of 21mmol/L cocaine in an acute fatal overdose.
In addition, Karch et al27 found that 3.6 mmol/L is the mean
concentration in cocaine-poisoned patients. However, there is
also evidence that cocaine concentration can go up to 100 to
1000 mmol/L in the plasma of drug addicts. For example, in
the study by Blaho et al,25 a concentration up to 120 mmol/L
was observed in a surviving patient. Notably, a study by
Peretti et al28 described that the serum concentration exceeded
1000 mmol/L after an acute fatal overdose. Although Mittle-
man and Wetli26 reported the mean concentration of cocaine
at 21 mmol/L, the highest level was reported to be 70 mmol/L.
Similarly, in the study by Karch et al,27 the highest detected
cocaine concentration was 62 mmol/L. It is also critical to
consider that these reported concentrations aremost likely not
the peak concentrations in the plasma of cocaine addicts. This
is for the following reasons: i) the measurements of cocaine
concentrations in the plasma are almost always conducted a
few hours after cocaine use, ii) cocaine has a short half-life
(<60 minutes), and iii) peak cocaine concentrations are ach-
ieved within 5 seconds to 60 minutes, depending on mode of
administrations.23,24,53e55 However, we acknowledge that
concentrations >100 mmol/L may not be prevalent among
cocaine abusers, and the physiological relevance of our data is
unclear. Nevertheless, examining the effects of cocaine on
CD4þ T cells, albeit higher than physiological concentra-
tions, may help us elucidate the molecular interaction be-
tween cocaine and CD4þ T cells. These studies will shed
critical insights into the cellular signaling pathways andThe American Journal of Pathology - ajp.amjpathol.orgpharmacological and immunomodulatory effects of cocaine
on CD4þ T cells.
Although the mechanism by which cocaine reduces T-cell
numbers is unclear, the immune modulatory function of
cocaine has been suggested to play a role.50 Our data illus-
trated that cocaine treatment did not signiﬁcantly increase
immune activation of resting CD4þ T cells of HIV-1e
negative or HIV-1epositive individuals (Figure 4E and
Supplemental Figure S2). Although Ruiz et al50 described
increased immune activation among cocaine addicts, their
study examined effects of chronic cocaine abuse in contrast
to the acute exposure of cocaine used in our experiments.
Notably, in a follow-up study, Ruiz et al56 illustrated that
acute cocaine exposure did not alter T-cell activation, similar
to our ﬁndings on the effects of cocaine on CD4þ T-cell
immune activation. Carrico et al57 also described that stim-
ulant use (both cocaine and methamphetamine) is associated
with higher levels of immune activation among HIV-positive
persons taking ART. However, these authors compared im-
mune activation only among HIV-1epositive patients. Given
that HIV-1 infection causes immune activation, whether
these stimulants had a direct effect on immune activation
remained inconclusive. In addition, our data were derived in
the cultures of CD4þ T cells treated with only cocaine,
whereas Carrico et al57 conducted their studies in humans
that abuse both cocaine and methamphetamine.
We also tested the effects of cocaine on HIV-1 infection,
because HIV-1 infection is known to induce CD4þ T-cell
apoptosis.35 Our data showed that HIV-1eexposed resting
CD4þ T cells have a low level of infection and that cocaine
did not increase infectivity (Supplemental Figure S1). This933
Pandhare et alis in contrast to a recent report by Kim et al58 that suggested
that cocaine enhances HIV-1 infection in quiescent CD4þ T
cells. However, these authors used a low concentration of
cocaine (10 nmol/L), treated the cells for 3 days with
cocaine, and found a signiﬁcant difference in infection only
3 days after infection. Because our data were generated by
exposing cells for 24 hours, infection may not explain the
increase in apoptosis.
It is well documented that binding of HIV-1 envelope
protein to the CD4þ receptor and C-X-C chemokine 4/
CCR5 coreceptors of CD4þ T cells induces apoptosis.59e61
More important, ROS-mediated mitochondrial oxidative
stress plays a critical role in HIV-1einduced CD4þ T-cell
apoptosis.37e41 Furthermore, cocaine has also been shown
to increase ROS and mitochondrial membrane potential
in neuronal cells.62,63 Therefore, we tested whether
ROS-mediated oxidative stress plays a role in cocaine and
HIV-1einduced CD4þ T-cell apoptosis. Data in Figure 3
illustrated that cocaine had a minimal impact on ROS and
mitochondrial membrane potential. However, in virion-
exposed cells, cocaine signiﬁcantly increased ROS levels
and mitochondrial depolarization. Notably, the synergy
between cocaine and HIV-1 was abrogated with heat-
inactivated or VSV-Gepseudotyped virions (Figure 2,
CeE). Therefore, our data strongly suggest that the syner-
gistic effect of cocaine and HIV-1 on CD4þ T-cell apoptosis
is mediated by increased oxidative stress that is mostly
likely mediated by the HIV-1 envelope protein.
A direct link between cocaine use and HIV-1 disease
progression remains contentious because substance use is
often associated with reduced ART/nonadherence to ART.
Furthermore, history and route of drug use, amount and
formulation of drug used, single or concurrent use of other
drugs, and poor nutrition can also inﬂuence outcomes of
HIV-1 disease. Our ex vivo model alleviates many of these
challenges and measures effects of cocaine and HIV-1 on
CD4þ T-cell apoptosis. Therefore, we tested the effects of
cocaine on CD4þ T-cell apoptosis using PBMCs from 15
ART-naïve patients. We treated the PBMCs of HIV-
1einfected patients only with cocaine, assuming that these
cells are exposed to HIV-1 because these individuals had a
viral load ranging from 20,000 to 100,000 RNA copies/mL.
We also postulated that the resting CD4þ T cells are unin-
fected because a small percentage (0.01%) of resting CD4þ
T cells in HIV-1 patients are infected.50 Surprisingly, we did
not observe a synergy on CD4þ T-cell apoptosis
(Figure 4A). Because increased levels of apoptosis were
observed only when cells from healthy donors were treated
with virions at 50 ng/mL of p24 (Figure 2), we calculated
the amount of circulating virions from RNA copy
numbers.64 We found that the viral load of the patients used
in this study approximated between 60 and 300 pg/mL of
p24 equivalent. Therefore, our data imply that acute cocaine
abuse may have limited impact on CD4þ T-cell decline in
patients with a viral load <100,000 RNA copies/mL. This is
consistent with data reported by Duncan et al,65 which934showed that cocaine use was associated with CD4þ T-cell
decline in patients with viral loads >100,000 copies/mL.
Although Baum et al3 reported that cocaine abuse may
accelerate CD4þ T-cell decline in patients with a viral load
<100,000 RNA copies/mL, they found that crack-cocaine,
not cocaine powder, had an effect on CD4þ T-cell decline.
Because we used cocaine powder, it is possible that crack and
powder forms of cocaine may have distinct effects on CD4þ
T-cell decline. Notably, viral loads >100,000 copies/mL are
generally seen among patients with acute infection or high
levels of chronic viremia.66,67 Therefore, it is plausible that
cocaine abuse may aggravate CD4þ T-cell decline in acutely
infected patients or patients with high levels of chronic
viremia. In that scenario, the interaction between cocaine
abuse and HIV-1 infection may signiﬁcantly worsen HIV-1
disease progression. However, further research is needed to
better understand the molecular interplay between cocaine
abuse and HIV-1 disease progression.Supplemental Data
Supplemental material for this article can be found at
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